Latest / The Well-Built Life / Beyond Benign: Navigating Prostate Cancer
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:13Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:18Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:22Speaker 1: and let's dive in. So, to start things off, let's
- 0:26Speaker 1: dive into the prevalence of prostate cancer. It's the most
- 0:29Speaker 1: common cancer among American men, with over 300,000 new cases
- 0:33Speaker 1: reported each year. By age 80, roughly 60% of men
- 0:38Speaker 1: have prostate cancer, even if they don't show symptoms. That's
- 0:42Speaker 1: a staggering number once you take a closer look, right?
- 0:46Speaker 1: Despite the high incidence, the mortality rate from prostate cancer
- 0:50Speaker 1: is surprisingly low. Very few men actually die from it.
- 0:55Speaker 1: which suggests that most cases are either benign or slow-growing.
- 1:00Speaker 1: This leads us to question the necessity of aggressive treatment
- 1:03Speaker 1: in many cases.
- 1:04Speaker 2: Exactly, which brings up an interesting contradiction. If the mortality
- 1:09Speaker 2: rate is so low, what explains the push for widespread screenings?
- 1:13Speaker 2: The PSA test has long been the go-to, but it
- 1:16Speaker 2: turns out it might not be as accurate or necessary
- 1:19Speaker 2: as we thought.
- 1:20Speaker 1: You are spot on. The PSA test has a questionable
- 1:23Speaker 1: track record. For instance, Dr. Donald Sackner, who has been
- 1:27Speaker 1: vocal about its overuse, says it has become more of
- 1:31Speaker 1: a business than a means to improve public health. He
- 1:34Speaker 1: argues that the test leads to over-diagnosis, and the complications
- 1:38Speaker 1: of biopsies and other treatments are a nightmare for many men.
- 1:42Speaker 2: And yet, the test is so ingrained in our medical practices.
- 1:45Speaker 2: The issue lies in how we interpret the results. Many
- 1:49Speaker 2: men are caught in the crossfire, getting unnecessary treatments that
- 1:53Speaker 2: can have serious side effects. That's why it's crucial to
- 1:56Speaker 2: understand the nuances of PSA readings.
- 1:59Speaker 1: Exactly. Speaking of which, the velocity of change in PSA
- 2:03Speaker 1: levels is important, and a significant increase over 0.75 ngml
- 2:08Speaker 1: per year is a red flag, but there are newer
- 2:12Speaker 1: tests like the PHYS that can help clarify whether a
- 2:14Speaker 1: biopsy is necessary. It's all about getting the right balance.
- 2:18Speaker 2: True, but let's not forget the broader context. Nutritional and
- 2:23Speaker 2: environmental factors play a key role. For example, sufficient vitamin
- 2:28Speaker 2: D can slow prostate growth by 40% as the receptors
- 2:32Speaker 2: are present and active. And environmental factors like senoestrogens can
- 2:37Speaker 2: contribute to prostate enlargement. We need to educate ourselves on
- 2:41Speaker 2: these things too.
- 2:42Speaker 1: That's a vital point. And on top of this, we
- 2:45Speaker 1: need to think about how we can reform screening practices
- 2:48Speaker 1: to be more precise. Overdiagnosis and overtreatment are major issues,
- 2:54Speaker 1: and we need to focus on ensuring that the screening
- 2:56Speaker 1: process itself is as accurate and informative as possible. Absolutely.
- 3:01Speaker 2: Precision medicine, in this case, could be a game-changer. Tailoring
- 3:05Speaker 2: care to specific subtypes of prostate cancer, whether they are
- 3:09Speaker 2: turtles or rabbits, could lead to more effective targeted treatment.
- 3:14Speaker 2: And as for prevention, a low fasting insulin level of
- 3:17Speaker 2: under 5 is highly recommended. It's not just about the prostate,
- 3:21Speaker 2: but overall health.
- 3:22Speaker 1: Well said. And as we always emphasize on the show,
- 3:26Speaker 1: educating ourselves on these issues, from understanding our risk factors
- 3:31Speaker 1: to making informed decisions about screening, is key to staying
- 3:35Speaker 1: healthy and well-informed. Let's talk more about the nuances of
- 3:39Speaker 1: diagnosing prostate cancer, specifically the role of the PSA test.
- 3:44Speaker 1: It's a critical tool, but how reliable and necessary is it, really?
- 3:49Speaker 2: Right. And that's the crucial nuance here. The PSA test
- 3:53Speaker 2: is often the first step in detecting prostate cancer, but
- 3:56Speaker 2: it's not perfect. It measures levels of prostate-specific antigen in
- 4:01Speaker 2: the blood, and a high PSA could indicate anything from
- 4:04Speaker 2: benign prostatic hyperplasia to cancer.
- 4:07Speaker 1: Exactly. Which brings up an interesting contradiction. While it can
- 4:11Speaker 1: catch cancer early, PSA tests are sometimes criticized for leading
- 4:16Speaker 1: to unnecessary biopsies. Can you explain more about Dr. Sackner's
- 4:21Speaker 1: criticism of the PSA test?
- 4:23Speaker 2: Sure. Dr. Sackner argues that SA testing has become more
- 4:26Speaker 2: of a business opportunity than a health necessity. To raise
- 4:30Speaker 2: a lot of pressure to diagnose prostate cancer, which might
- 4:33Speaker 2: lead to overtreatment, it's important to consider the potential risks
- 4:37Speaker 2: of biopsies and aggressive treatments, especially when many cases turn
- 4:41Speaker 2: out to be slow-growing or benign.
- 4:43Speaker 1: True, and the distinction between cancer subtypes can be quite variable.
- 4:48Speaker 1: You mentioned turtles, slow birds, and rabbits. Can you elaborate
- 4:54Speaker 1: on what those terms mean?
- 4:56Speaker 2: Absolutely. Turtles are cancers that basically stay dormant and don't
- 5:00Speaker 2: require immediate intervention. About 40 to 50% of prostate cancers
- 5:05Speaker 2: fall into this category. Slow birds are less aggressive but
- 5:09Speaker 2: might still need monitoring. Only 10 to 20% of prostate
- 5:13Speaker 2: cancers are classified as rabbits, and these are the most
- 5:17Speaker 2: aggressive ones. Understanding these different types is key to individualized
- 5:22Speaker 2: treatment plans.
- 5:23Speaker 1: And that brings us to the complexity of diagnosis. What
- 5:27Speaker 1: factors should doctors consider besides the PSA test when evaluating
- 5:31Speaker 1: a patient?
- 5:32Speaker 2: Doctors need to look at the velocity of the PSA
- 5:35Speaker 2: trend and use tools like the Prostate Health Index, PHI,
- 5:39Speaker 2: to better assess the need for a biopsy. A rapid
- 5:42Speaker 2: increase in PSA levels could indicate more aggressive cancer. whereas
- 5:46Speaker 2: a stable or slowly rising level might suggest a less
- 5:50Speaker 2: urgent case.
- 5:50Speaker 1: It's fascinating how the landscape is shifting. I have also
- 5:54Speaker 1: heard about environmental factors contributing to prostate issues. Things like
- 5:59Speaker 1: vitamin D and insulin levels seem particularly important.
- 6:02Speaker 2: Yes, vitamin D levels can have a large impact. Sufficient
- 6:06Speaker 2: levels of vitamin D can reduce prostate size by 40%,
- 6:11Speaker 2: thanks to its involvement in prostate growth regulation. and excess
- 6:15Speaker 2: insulin can make androgen receptors more sensitive, promoting prostate growth.
- 6:20Speaker 2: Environmental factors like xenoestrogens can further contribute to these issues,
- 6:25Speaker 2: making the interplay between diet and environment crucial.
- 6:28Speaker 1: That's a lot to take in, but it underscores the
- 6:31Speaker 1: importance of not just treating prostate disease, but also preventing it.
- 6:36Speaker 1: What specific actions can men take to reduce their risks?
- 6:40Speaker 2: Keeping a healthy diet, maintaining a normal fasting insulin level
- 6:44Speaker 2: below 5, and ensuring adequate vitamin D levels are good starts.
- 6:48Speaker 2: These not only help with the prostate, but can also
- 6:51Speaker 2: contribute to overall health.
- 6:53Speaker 1: Absolutely. It's all about making informed choices and, as we
- 6:58Speaker 1: always say on the show, staying on top of your
- 7:00Speaker 1: health through education and proactive measures.
- 7:03Speaker 2: Right, and that's the crucial nuance here. In the grand
- 7:07Speaker 2: scheme of things, we need to ask ourselves just how
- 7:09Speaker 2: accurate is the PSA test, and is it as beneficial
- 7:13Speaker 2: as the medical community initially claimed?
- 7:15Speaker 1: Exactly, which brings up an interesting contradiction. The PSA test
- 7:19Speaker 1: was marketed as a lifesaver, but now we have experts
- 7:23Speaker 1: like Dr. Sackner questioning its legitimacy. How does this reflect
- 7:27Speaker 1: on the diagnostics industry as a whole?
- 7:30Speaker 2: Well, it's clear that the overdiagnosis issue isn't limited to
- 7:33Speaker 2: just the PSA test. It's a broader concern about how
- 7:37Speaker 2: we approach disease detection. We need to look at the
- 7:40Speaker 2: incentive structure here. The more tests and treatments that are sold,
- 7:44Speaker 2: the more revenue is generated. Right.
- 7:47Speaker 1: It's like playing whack-a-mole. The more you check for one problem,
- 7:51Speaker 1: the more potential issues you find, leading to a constant
- 7:55Speaker 1: cycle of testing and treatment. But let's dive deeper into
- 7:59Speaker 1: the role of vitamin D and insulin. Can you explain
- 8:03Speaker 1: how these factors impact prostate health? That's fascinating. So it's
- 8:07Speaker 1: not just about finding a marker that indicates cancer. It's
- 8:11Speaker 1: about overall prevention and management. What about insulin? How does
- 8:16Speaker 1: that specifically affect prostate issues?
- 8:18Speaker 2: Insulin is key here. Excess levels can activate androgen receptors
- 8:23Speaker 2: and increase the production of insulin-like growth factors, both of
- 8:27Speaker 2: which can enlarge the prostate. Additionally, environmental factors like xenoestrogens
- 8:32Speaker 2: from plastics and pesticides can mimic estrogen and contribute to
- 8:36Speaker 2: the problem.
- 8:37Speaker 1: Got it. So, maintaining a healthy diet and managing insulin
- 8:41Speaker 1: levels could have a compounding effect on prostate health. But, wait,
- 8:47Speaker 1: how does all of this practical information translate into actionable
- 8:50Speaker 1: steps for men who are wary of overdiagnosis?
- 8:53Speaker 2: Well, the first step is awareness. Men should get regular checkups,
- 8:58Speaker 2: but the focus should be on overall wellness rather than
- 9:01Speaker 2: just cancer screening. The fasting insulin test you mentioned is
- 9:05Speaker 2: crucial because keeping it under 5 can protect against the
- 9:09Speaker 2: issues we discussed.
- 9:10Speaker 1: Right. And it's about more than just the prostate. This
- 9:14Speaker 1: helps the whole body. It's about empowering men to take
- 9:19Speaker 1: a holistic approach to health, not just reacting to potential
- 9:23Speaker 1: cancer diagnoses.
- 9:25Speaker 2: Absolutely. We need to move away from a one-size-fits-all approach
- 9:29Speaker 2: and focus on personalized health plans. And of course, educating
- 9:33Speaker 2: men about the nuances of prostate health and the realities
- 9:36Speaker 2: of overdiagnosis.
- 9:37Speaker 1: Exactly. Let's end this segment by driving home the message
- 9:41Speaker 1: that informed choice and proactive wellness are the pillars of
- 9:44Speaker 1: staying healthy. And that starts with a simple blood test
- 9:48Speaker 1: and a healthy lifestyle. So, let's dive into some of
- 9:51Speaker 1: the key debates around commercialized screening and precision medicine. Dr. Sackner,
- 9:57Speaker 1: the scientist who criticized the PSA test has brought up
- 10:01Speaker 1: some really interesting points about how it's become more of
- 10:03Speaker 1: a business than a tool for early detection. What are
- 10:07Speaker 1: your thoughts on that, Thomas?
- 10:09Speaker 2: It's definitely a sobering thought. The business angle has turned
- 10:13Speaker 2: the PSA test into a lucrative industry, leading many to
- 10:16Speaker 2: be overdiagnosed. I mean, imagine having a test that, While
- 10:20Speaker 2: initially life-saving, can also cause significant stress and sometimes unnecessary
- 10:24Speaker 2: invasive procedures. It's a complex web of incentives that go
- 10:28Speaker 2: beyond the medical community.
- 10:30Speaker 1: Exactly. And it's not just about the test itself, but
- 10:33Speaker 1: how it's used. For example, the Prostate Health Index, PHY
- 10:37Speaker 1: test can help determine the need for a biopsy, which
- 10:40Speaker 1: is a significant surgical intervention. There are so many gray
- 10:44Speaker 1: areas here. especially when you factor in the commercial aspects.
- 10:48Speaker 2: Right. And this brings us to another unsolved question. How
- 10:52Speaker 2: do we better distinguish between the three subtypes of prostate
- 10:55Speaker 2: cancer to provide more precise treatment? I mean, knowing that
- 10:58Speaker 2: 40 to 50% of cancers are benign or slow. Growing
- 11:03Speaker 2: is crucial. But how can we accurately identify which cancers
- 11:06Speaker 2: need immediate care and which ones can be watched more closely?
- 11:09Speaker 1: That's a great point. And let's not forget the role
- 11:12Speaker 1: of vitamin D. I recently read that maintaining optimal vitamin
- 11:16Speaker 1: D levels can slow prostate growth by 40%. It's fascinating
- 11:21Speaker 1: how something as simple as a blood test can have
- 11:23Speaker 1: such profound impacts on prevention and management. It really emphasizes
- 11:28Speaker 1: the importance of preventive medicine.
- 11:30Speaker 2: Absolutely. And speaking of prevention, how can we integrate more
- 11:35Speaker 2: holistic approaches into treatment? For instance, addressing lifestyle factors like
- 11:40Speaker 2: fasting insulin levels. I mean... A recommendation to get a
- 11:44Speaker 2: fasting insulin test is not just about the prostate, it's
- 11:48Speaker 2: about keeping the whole body in check.
- 11:50Speaker 1: That's a very practical approach. Moving forward, I think precision
- 11:54Speaker 1: medicine holds huge potential. Tailoring treatment to the specific characteristics
- 11:59Speaker 1: of the cancer subtype could be transformative. but we need
- 12:02Speaker 1: better tools and markers to make that kind of personalized
- 12:06Speaker 1: care possible.
- 12:07Speaker 2: Agreed. And the future looks promising with advances in diagnostic
- 12:11Speaker 2: tools and technologies. They might offer more specific cancer markers,
- 12:15Speaker 2: reducing the risk of over-diagnosis and unnecessary interventions. It's a
- 12:20Speaker 2: delicate balance, but with the right policies and guidelines, we
- 12:23Speaker 2: could see significant progress.
- 12:25Speaker 1: Indeed. It's about moving from a one-size-fits-all all approach to
- 12:30Speaker 1: a personalized, nuanced understanding of prostate health. This is where
- 12:35Speaker 1: the future of diagnostics and treatments lies, and it's an
- 12:39Speaker 1: exciting time to be part of this conversation. As we
- 12:42Speaker 1: wrap up this episode on the future of prostate care,
- 12:45Speaker 1: let's delve into the advanced diagnostic tools and personalized treatment
- 12:49Speaker 1: strategies that could truly transform how we handle these conditions.
- 12:53Speaker 2: Absolutely. The horizon is promising with innovations like multi-parametric MRI
- 12:59Speaker 2: and novel biomarkers that could make a significant impact. For instance,
- 13:04Speaker 2: the ability to precisely visualize the prostate using MRI with
- 13:08Speaker 2: contrast is a game-changer.
- 13:10Speaker 1: That's right. It's all about clarity. These tools not only
- 13:14Speaker 1: improve diagnostic accuracy, but also reduce the need for invasive biopsies,
- 13:20Speaker 1: which can be uncomfortable and risky. It's about precision medicine.
- 13:24Speaker 1: where treatment is tailored to the individual.
- 13:27Speaker 2: Exactly. And speaking of tailored approaches, let's consider the role
- 13:31Speaker 2: of genomic profiling. With tools like next-generation sequencing, we can
- 13:36Speaker 2: now map out the genetic landscape of tumors to identify
- 13:40Speaker 2: the most effective treatments.
- 13:41Speaker 1: It's fascinating how it works. By analyzing the specific mutations
- 13:46Speaker 1: in a patient's tumor, doctors can prescribe drugs that target
- 13:50Speaker 1: those exact mutations, potentially making treatments more effective and reducing
- 13:55Speaker 1: side effects.
- 13:56Speaker 2: And that's not all. Therese also a strong push towards
- 13:59Speaker 2: preventive measures. Keeping an eye on vitamin D levels, for instance,
- 14:03Speaker 2: could have a profound impact. Remember, adequate vitamin D can
- 14:08Speaker 2: significantly slow prostate growth. True.
- 14:11Speaker 1: It's a holistic approach. Let's not forget the power of
- 14:14Speaker 1: lifestyle changes too. Managing insulin levels and reducing environmental exposures
- 14:20Speaker 1: can play a crucial role in safeguarding prostate health.
- 14:24Speaker 2: Well said, and it's refreshing to see an integrated strategy
- 14:27Speaker 2: that emphasizes both precision in treatment and prevention. It brings
- 14:32Speaker 2: us to a point where we can truly focus on
- 14:34Speaker 2: quality of life rather than just the quantity of treatment.
- 14:38Speaker 1: Exactly. The future of care is about personalized plans that
- 14:42Speaker 1: consider both the specifics of the condition and the individual's
- 14:46Speaker 1: overall health. It's a delicate balance, but with the right tools,
- 14:50Speaker 1: we can get it right.
- 14:51Speaker 2: Indeed. As we look to the future … Let's aim
- 14:54Speaker 2: for systems that prioritize clear communication and shared decision-making, ensuring
- 14:59Speaker 2: that patients are fully informed and involved in their care journey.
- 15:03Speaker 1: That brings us to the end of today's episode. Thank
- 15:06Speaker 1: you so much for spending part of your day with me.
- 15:08Speaker 1: If you found this episode's tips helpful and want to
- 15:11Speaker 1: make sure you don't miss the next conversation, please take
- 15:14Speaker 1: a quick second to hit that subscribe or follow button
- 15:17Speaker 1: on whatever platform you are listening on. It's a completely
- 15:21Speaker 1: free way to support the show and helps more people
- 15:23Speaker 1: find us. This podcast is independently produced, so if you
- 15:27Speaker 1: are ever in a position where you would like to
- 15:30Speaker 1: help keep it running, we do accept small donations. You
- 15:34Speaker 1: can find a link right in the episode description below
- 15:37Speaker 1: to buy us a coffee or contribute what you can.
- 15:39Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 15:44Speaker 1: and we will talk again soon.